Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 16.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,830 shares of the medical research company’s stock after buying an additional 1,509 shares during the period. Verdence Capital Advisors LLC’s holdings in Edwards Lifesciences were worth $826,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Advisors Asset Management Inc. increased its stake in shares of Edwards Lifesciences by 0.3% during the first quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after acquiring an additional 117 shares during the period. Apollon Wealth Management LLC increased its position in shares of Edwards Lifesciences by 1.0% during the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after purchasing an additional 119 shares during the period. Geller Advisors LLC raised its stake in shares of Edwards Lifesciences by 6.5% in the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock worth $231,000 after buying an additional 120 shares in the last quarter. Martin Capital Advisors LLP lifted its holdings in shares of Edwards Lifesciences by 0.5% in the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after buying an additional 128 shares during the period. Finally, Legacy Wealth Asset Management LLC boosted its stake in Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after buying an additional 134 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $85.94 on Monday. The company has a market capitalization of $51.73 billion, a PE ratio of 37.37, a PEG ratio of 4.26 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The company’s 50 day moving average price is $90.15 and its 200 day moving average price is $78.42. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.64 earnings per share. Research analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares in the company, valued at $2,980,774.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 194,004 shares of company stock valued at $17,166,254. 1.27% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on EW shares. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target on the stock in a research report on Friday, February 2nd. Oppenheimer increased their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Finally, Royal Bank of Canada raised their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.